GlassScriptPhysician profile
Julie Feldstein
NPI 1841270832
$5,728.65
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $16.75 · 2021: $5,489.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $3,478.50 | 2021 | |
| Blueprint Medicines Corporation | $2,010.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $122.03 | 2019 | |
| Seagen INC. | $100.87 | 2019 | |
| Stemline Therapeutics INC. | $16.75 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Feldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.